


- [0169] AG. The method of any one of Paragraphs W-AF, wherein the subject is suffering from epilepsy.
- [0170] AH. The method of any one of Paragraphs W-AG, wherein the effective amount is an amount effective to treat epilepsy.
- [0171] AI. A method of increasing glycolytic flux in a subject, the method comprising administering to the subject an effective amount of a compound of any one of Paragraphs A-D.
- [0172] AJ. The method of Paragraph AI, wherein the subject is suffering from a neurodegenerative disease.
- [0173] AK. The method of Paragraph AI or Paragraph AJ, wherein the neurodegenerative disease comprises Alzheimer's disease.
- [0174] AL. The method of any one of Paragraphs AI-AK, wherein the effective amount is an amount effective to treat Alzheimer's disease.
- [0175] AM. The method of any one of Paragraphs AI-AL, wherein the neurodegenerative disease comprises Parkinson's disease.
- [0176] AN. The method of any one of Paragraphs AI-AM, wherein the effective amount is an amount effective to treat Parkinson's disease.
- [0177] AO. The method of any one of Paragraphs AI-AN, wherein the subject is suffering from amyotrophic lateral sclerosis.
- [0178] AP. The method of any one of Paragraphs AI-AO, wherein the effective amount is an amount effective to treat amyotrophic lateral sclerosis.
- [0179] AQ. The method of any one of Paragraphs AI-AP, wherein the subject is suffering from multiple sclerosis.
- [0180] AR. The method of any one of Paragraphs AI-AQ, wherein the effective amount is an amount effective to treat multiple sclerosis.
- [0181] AS. The method of any one of Paragraphs AI-AR, wherein the subject is suffering from epilepsy.
- [0182] AT. The method of any one of Paragraphs AI-AS, wherein the effective amount is an amount effective to treat epilepsy.
- [0183] AU. A method of treating a subject suffering from a neurodegenerative disease, the method comprising administering an effective amount of a compound of any one of Paragraphs A-D to the subject.
- [0184] AV. The method of Paragraph AU, wherein the neurodegenerative disease comprises Alzheimer's disease.
- [0185] AW. The method of Paragraph AU or Paragraph AV, wherein the effective amount is an amount effective to treat Alzheimer's disease.
- [0186] AX. The method of any one of Paragraphs AU-AW, wherein the neurodegenerative disease comprises Parkinson's disease.
- [0187] AY. The method of any one of Paragraphs AU-AX, wherein the effective amount is an amount effective to treat Parkinson's disease.
- [0188] AZ. The method of any one of Paragraphs AU-AY, wherein the neurodegenerative disease comprises amyotrophic lateral sclerosis.
- [0189] BA. The method of any one of Paragraphs AU-AZ, wherein the effective amount is an amount effective to treat amyotrophic lateral sclerosis.
- [0190] BB. A method for increasing ketone levels in a subject, the method comprising administering to the subject a compound of any one of Paragraphs A-D.


- [0191] BC. The method of Paragraph BB, wherein the method comprises administering to the subject an effective amount of the compound, wherein the effective amount is an amount that increases ketone levels in the subject.
- [0192] BD. The method of Paragraph BB or Paragraph BC, wherein increasing ketone levels in the subject comprises increasing ketone levels in blood of the subject by administering the compound.
- [0193] BE. The method of any one of Paragraphs BB-BD, wherein increasing ketone levels in the subject comprises increasing ketone levels in plasma of the subject by administering the compound.
- [0194] BF. The method of any one of Paragraphs BB-BE, wherein increasing ketone levels in the subject comprises increasing ketogenesis in the subject by administering the compound.
- [0195] BG. The method of any one of Paragraphs BB-BF, wherein increasing ketone levels in the subject comprises an increase of ketones derived from administering the compound.
- [0196] BH. A method of treating a subject suffering from multiple sclerosis, the method comprising administering an effective amount of a compound of any one of Paragraphs A-D to the subject, wherein the effective amount is an amount effective to treat multiple sclerosis.
- [0197] BI. A method of treating a subject suffering from epilepsy, the method comprising administering an effective amount of a compound of any one of Paragraphs A-D to the subject, wherein the effective amount is an amount effective to treat epilepsy.
- [0198] Other embodiments are set forth in the following claims.

1. A compound of Formula I



or a pharmaceutically acceptable salt and/or solvate thereof,

wherein  $\text{R}^1$  and  $\text{R}^2$  are each independently



provided that at least one of  $\text{R}^1$  and  $\text{R}^2$  is not H.